Elem Biotech is a technology-driven company dedicated to the R&D of high-throughput cell editing tools, with core technologies derived from the University of California, Berkeley. The company has completed knockout experimental verification for 19, 883 genes of the human whole genome.

Based on its industrial intelligent high-throughput in vitro cell editing platform, Elem Biotech provides customers with customized services including gene knockout, overexpression, point mutation, and in situ/site-specific knock-in, as well as a series of products such as ready-made gene-edited cells and gene knockout kits, facilitating new drug development and basic research. As a benchmark enterprise in the field of high-throughput gene knockout array libraries in China, Elem Biotech has built an automated and high-throughput gene knockout platform, achieving a production capacity of over 1, 000 KO cells per month. Leveraging its self-developed Harbor cell line and pCargo plasmid vector system, the company can efficiently construct stable cell lines within two weeks.

The team at Elem Biotech has always adhered to the core values of continuous innovation, product optimization, traceability and efficiency improvement, and is committed to supporting new drug development and basic scientific research. As the first enterprise in China, it has completed the layout of a comprehensive product portfolio covering reagents, equipment, ready-made cells and personalized customized services.